| OTC Markets: PROT
Proteonomix, Inc. is a biotechnology company engaged in the discovery and development of stem cell therapeutic and cosmeceutical products. It is developing pre clinical-stage therapeutic agents and treatments for diabetes, heart, and lung diseases. The company's discoveries involve non embryonic stem cell treatments. It operates through the following segments: the sperm bank division, the stem-cell division, the skin care products division, PRTMI, Thor and StromaCel. Proteonomix was founded by Michael Moshe Cohen on June 26, 1995 and is headquartered in Hawthorne, NJ.